Tvardi Therapeutics, Inc. (TVRD) Stock Score, Valuation & Financial Research

Tvardi Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for TVRD

Tvardi Therapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 1.08. These figures are a research snapshot, not a buy or sell recommendation.

What Tvardi Therapeutics, Inc. does

Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Tvardi Therapeutics is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model relies on raising capital through equity offerings and other financing activities to fund the research and development of its proprietary small molecule inhibitors targeting STAT3 for the treatment of inflammatory and proliferative diseases.

Products and services

  • The company is developing a pipeline of STAT3 inhibitors, including its lead clinical-stage candidates TTI-101 and TTI-109, which are being evaluated for various indications such as fibrosis-driven diseases and hepatocellular carcinoma.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) — The company relies on third-party service providers for clinical trial management, drug substance manufacturing, and formulation development. Source

Business strengths to evaluate

  • Proprietary STAT3 inhibitor platform Source

Business risks and research considerations

  • History of operating losses and dependence on future financing Source
  • Clinical trial failure and regulatory approval uncertainty Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

TVRD financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 1.08
Market capitalization:
10.13M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -26.06M
Free cash flow:
USD -23.5M
Cash:
USD 15.77M
Total debt:
USD 145K
EPS:
USD -2.79

What stands out

  • Free cash flow is USD -23.5M, negative for the stored period.
  • The balance sheet shows USD 15.77M of cash versus USD 145K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 15.62M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for TVRD

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can TVRD fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is TVRD likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for TVRD to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of TVRD's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research TVRD

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.